|
1
|
Omar E: Current concepts and future of
noninvasive procedures for diagnosing oral squamous cell carcinoma
- a systematic review. Head Face Med. 11:62015. View Article : Google Scholar :
|
|
2
|
Chiang CM: Brd4 engagement from chromatin
targeting to transcriptional regulation: Selective contact with
acetylated histone H3 and H4.F1000. Biol Rep. 1:982009.
|
|
3
|
Wu X, Liu D, Tao D, Xiang W, Xiao X, Wang
M, Wang L, Luo G, Li Y, Zeng F, et al: BRD4 regulates EZH2
transcription through up-regulation of C-MYC and represents a novel
therapeutic target in bladder cancer. Mol Cancer Ther.
15:1029–1042. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Delmore JE, Issa GC, Lemieux ME, Rahl PB,
Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et
al: BET bromodomain inhibition as a therapeutic strategy to target
c-Myc. Cell. 146:904–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liao YF, Wu YB, Long X, Zhu SQ, Jin C, Xu
JJ and Ding JY: High level of BRD4 promotes non-small cell lung
cancer progression. Oncotarget. 7:9491–9500. 2016.PubMed/NCBI
|
|
6
|
Wedeh G, Cerny-Reiterer S, Eisenwort G,
Herrmann H, Blatt K, Hadzijusufovic E, Sadovnik I, Müllauer L,
Schwaab J, Hoffmann T, et al: Identification of
bromodomain-containing protein-4 as a novel marker and epigenetic
target in mast cell leukemia. Leukemia. 29:2230–2237. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li GQ, Guo WZ, Zhang Y, Seng JJ, Zhang HP,
Ma XX, Zhang G, Li J, Yan B, Tang HW, et al: Suppression of BRD4
inhibits human hepatocellular carcinoma by repressing MYC and
enhancing BIM expression. Oncotarget. 7:2462–2474. 2016.
|
|
8
|
Zuber J, Shi J, Wang E, Rappaport AR,
Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al:
RNAi screen identifies Brd4 as a therapeutic target in acute
myeloid leukaemia. Nature. 478:524–528. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shi J, Cao J and Zhou BP: Twist-BRD4
complex: Potential drug target for basal-like breast cancer. Curr
Pharm Des. 21:1256–1261. 2015. View Article : Google Scholar
|
|
10
|
Wu T and Donohoe ME: The converging roles
of BRD4 and gene transcription in pluripotency and oncogenesis. RNA
Dis. 2:pii: e894. 2015.PubMed/NCBI
|
|
11
|
Leptin M: twist and snail as positive and
negative regulators during Drosophila mesoderm development. Genes
Dev. 5:1568–1576. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maestro R, Dei Tos AP, Hamamori Y,
Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH and
Hannon GJ: twist is a potential oncogene that inhibits apoptosis.
Genes Dev. 13:2207–2217. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q,
Tang F, Chen ZQ, Liu XP and Xu ZD: Twist1-mediated
adriamycin-induced epithelial-mesenchymal transition relates to
multidrug resistance and invasive potential in breast cancer cells.
Clin Cancer Res. 15:2657–2665. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD
and Wang LH: Twist transcriptionally up-regulates AKT2 in breast
cancer cells leading to increased migration, invasion, and
resistance to paclitaxel. Cancer Res. 67:1979–1987. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang
Q, Lin Y, Li J, Kang T, Tao M, et al: Disrupting the interaction of
BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like
breast cancer. Cancer Cell. 25:210–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wahlström T and Arsenian Henriksson M:
Impact of MYC in regulation of tumor cell metabolism. Biochim
Biophys Acta. 1849:563–569. 2015. View Article : Google Scholar
|
|
17
|
Dang CV: MYC on the path to cancer. Cell.
149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vita M and Henriksson M: The Myc
oncoprotein as a therapeutic target for human cancer. Semin Cancer
Biol. 16:318–330. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nesbit CE, Tersak JM and Prochownik EV:
MYC oncogenes and human neoplastic disease. Oncogene. 18:3004–3016.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lüscher B and Vervoorts J: Regulation of
gene transcription by the oncoprotein MYC. Gene. 494:145–160. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Delgado MD and León J: Myc roles in
hematopoiesis and leukemia. Genes Cancer. 1:605–616. 2010.
View Article : Google Scholar
|
|
22
|
Rahl PB, Lin CY, Seila AC, Flynn RA,
McCuine S, Burge CB, Sharp PA and Young RA: c-Myc regulates
transcriptional pause release. Cell. 141:432–445. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Filippakopoulos P, Qi J, Picaud S, Shen Y,
Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et
al: Selective inhibition of BET bromodomains. Nature.
468:1067–1073. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shimamura T, Chen Z, Soucheray M,
Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi
J, et al: Efficacy of BET bromodomain inhibition in Kras-mutant
non-small cell lung cancer. Clin Cancer Res. 19:6183–6192. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lenhart R, Kirov S, Desilva H, Cao J, Lei
M, Johnston K, Peterson R, Schweizer L, Purandare A, Ross-Macdonald
P, et al: Sensitivity of small cell lung cancer to BET inhibition
is mediated by regulation of ASCL1 gene expression. Mol Cancer
Ther. 14:2167–2174. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang L, Tong Y, Zhang X, Pan M and Chen
S: Arsenic sulfide combined with JQ1, chemotherapy agents, or
celecoxib inhibit gastric and colon cancer cell growth. Drug Des
Devel Ther. 9:5851–5862. 2015.PubMed/NCBI
|
|
27
|
Henssen A, Thor T, Odersky A, Heukamp L,
El-Hindy N, Beckers A, Speleman F, Althoff K, Schäfers S, Schramm
A, et al: BET bromodomain protein inhibition is a therapeutic
option for medulloblastoma. Oncotarget. 4:2080–2095. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Loosveld M, Castellano R, Gon S, Goubard
A, Crouzet T, Pouyet L, Prebet T, Vey N, Nadel B, Collette Y, et
al: Therapeutic targeting of c-Myc in T-cell acute lymphoblastic
leukemia, T-ALL. Oncotarget. 5:3168–3172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Georgy SR, Cangkrama M, Srivastava S,
Partridge D, Auden A, Dworkin S, McLean CA, Jane SM and Darido C:
Identification of a novel proto-oncogenic network in head and neck
squamous cell carcinoma. J Natl Cancer Inst. 107:pii: djv152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu J, Xie F, Bao X, Chen W and Xu Q:
miR-300 inhibits epithelial to mesenchymal transition and
metastasis by targeting Twist in human epithelial cancer. Mol
Cancer. 13:1212014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang YH, Sui XM, Sui YN, Zhu QW, Yan K,
Wang LS, Wang F and Zhou JH: BRD4 induces cell migration and
invasion in HCC cells through MMP-2 and MMP-9 activation mediated
by the Sonic hedgehog signaling pathway. Oncol Lett. 10:2227–2232.
2015.PubMed/NCBI
|
|
32
|
Ambrosini G, Sawle AD, Musi E and Schwartz
GK: BRD4-targeted therapy induces Myc-independent cytotoxicity in
Gnaq/11-mutatant uveal melanoma cells. Oncotarget. 6:33397–33409.
2015.PubMed/NCBI
|
|
33
|
Wang YH, Sui YN, Yan K, Wang LS, Wang F
and Zhou JH: BRD4 promotes pancreatic ductal adenocarcinoma cell
proliferation and enhances gemcitabine resistance. Oncol Rep.
33:1699–1706. 2015.PubMed/NCBI
|
|
34
|
Zhang Z, Ma P, Jing Y, Yan Y, Cai MC,
Zhang M, Zhang S, Peng H, Ji ZL, Di W, et al: BET bromodomain
inhibition as a therapeutic strategy in ovarian cancer by
downregulating FoxM1. Theranostics. 6:219–230. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gao X, Wu X, Zhang X, Hua W and Zhang Y,
Maimaiti Y, Gao Z and Zhang Y: Inhibition of BRD4 suppresses tumor
growth and enhances iodine uptake in thyroid cancer. Biochem
Biophys Res Commun. 469:679–685. 2016. View Article : Google Scholar
|
|
36
|
Lochrin SE, Price DK and Figg WD: BET
bromodomain inhibitors - a novel epigenetic approach in
castration-resistant prostate cancer. Cancer Biol Ther.
15:1583–1585. 2014. View Article : Google Scholar
|
|
37
|
Baker EK, Taylor S, Gupte A, Sharp PP,
Walia M, Walsh NC, Zannettino AC, Chalk AM, Burns CJ and Walkley
CR: BET inhibitors induce apoptosis through a MYC independent
mechanism and synergise with CDK inhibitors to kill osteosarcoma
cells. Sci Rep. 5:101202015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
McKeown MR and Bradner JE: Therapeutic
strategies to inhibit MYC. Cold Spring Harb Perspect Med. 4:42014.
View Article : Google Scholar
|
|
39
|
Kandela I, Jin HY and Owen K:
Reproducibility Project: Cancer Biology: Registered report: BET
bromodomain inhibition as a therapeutic strategy to target c-Myc.
Elife. 4:e070722015. View Article : Google Scholar
|
|
40
|
Conacci-Sorrell M, McFerrin L and Eisenman
RN: An overview of MYC and its interactome. Cold Spring Harb
Perspect Med. 4:a0143572014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Meyer N and Penn LZ: Reflecting on 25
years with MYC. Nat Rev Cancer. 8:976–990. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Entz-Werlé N, Stoetzel C, Berard-Marec P,
Kalifa C, Brugiere L, Pacquement H, Schmitt C, Tabone MD, Gentet
JC, Quillet R, et al: Frequent genomic abnormalities at TWIST in
human pediatric osteosarcomas. Int J Cancer. 117:349–355. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
da Silva SD, Alaoui-Jamali MA, Soares FA,
Carraro DM, Brentani HP, Hier M, Rogatto SR and Kowalski LP: TWIST1
is a molecular marker for a poor prognosis in oral cancer and
represents a potential therapeutic target. Cancer. 120:352–362.
2014. View Article : Google Scholar
|
|
44
|
Zheng L, Li N, Guo F, Jian XC, Jiang CH,
Yin P, Min AJ and Huang L: Twist-related protein 1 enhances oral
tongue squamous cell carcinoma cell invasion through β-catenin
signaling. Mol Med Rep. 11:2255–2261. 2015.
|
